-
[show abstract]
[hide abstract]
ABSTRACT: To describe a patient with prodromal dementia with Lewy bodies (DLB) manifesting as sertraline-induced parkinsonism.
Case report.
Tertiary referral center.
A 75-year-old man who initially presented with anxiety and depression along with mild cognitive impairment, later developed drug-induced parkinsonism because of sertraline treatment, and eventually showed symptoms and signs of probable DLB.
Sertraline treatment for depression.
: Clinical examination, magnetic resonance imaging, neuropsychologic test, and cardiac I-metaiodobenzylguanidine scintigraphy.
His parkinsonian symptoms, which became apparent after sertraline therapy, improved markedly after the discontinuation of the drug. When he started taking sertraline, he had no dementia but had mild cognitive impairment. However, he eventually showed most of the symptoms and signs to indicate probable DLB.
To our knowledge, there has been no report of sertraline-induced or aggravated parkinsonian motor symptoms in DLB patients. Our patient had a short period with neither dementia nor parkinsonism during the early stage of his illness, and this period might have been regarded as the preclinical stage of DLB in the natural course of his illness.
Alzheimer disease and associated disorders 09/2011; 26(2):191-3. · 2.88 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: To investigate if diabetes is more common in drug-induced parkinsonism patients. We performed a hospital-based retrospective case-control study on 44 drug-induced parkinsonism (DIP) patients, 177 Parkinson disease patients, and 176 acute stroke patients matched for age and sex who were seen over the same period at the same hospital. The frequency of diabetes, age-at onset and sex were compared between DIP and IPD or acute stroke. Multivariate analysis showed that patients with diabetes are more frequent in DIP compared with IPD (p<0.001, adjusted OR 5.48; 95% CI, 2.52-11.94). The frequency of diabetes in DIP was comparable to that in acute stroke patients (p=0.16, adjusted OR 0.62; 95% CI, 0.32-1.21). These data suggest that diabetes may be a risk factor for DIP. Drugs with dopamine receptor blocking potency should be avoided in elderly with diabetes.
Journal of the neurological sciences 05/2009; 284(1-2):140-3. · 2.32 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Short life expectancy influences decision-making when treating very old patients with acute ischemic stroke (AIS). We investigated mortality and survival duration in very old AIS patients (>or= 80 years) who received hospital care.
Mortality data were obtained from medical records, structured telephone inquiries, death certificates from the Korean National Statistical Office, and social security data 5+/-1.9 years after stroke onset. Age, gender, vascular risk factors, and functional outcomes from modified Rankin scales (MRS) at discharge were analyzed as predictors of mortality.
Among 134 patients, 92 (68.7%) died. On Kaplan-Meier analysis, duration of survival of patients aged 80-84 years was longer than those aged 85-89 or 90-94 (24+/-6.4, 8+/-7.3, 7+/-2.0 months, respectively, p=0.002). Duration of survival of patients discharged in a state of MRS 0-1 was longer than the remaining groups at 47+/-4.8 months (p<0.001). In Cox proportional hazard analysis, age and MRS at discharge were independent predictors of mortality.
Long-term outcomes of very old patients with AIS are not uniformly grave, therefore predictors of mortality and estimated duration of survival should be considered during decision-making for treatment.
Yonsei Medical Journal 06/2008; 49(3):400-4. · 1.14 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: An aging-suppressor gene, klotho, is a candidate factor for vascular disease because its deficiency leads to impaired endothelium-dependent vasodilation and impaired angiogenesis. We investigated the association of polymorphisms in klotho with ischemic stroke. We searched for sequence variants in promoter and exons of klotho gene. For the association study, selected variants were genotyped in control subjects and in patients with ischemic stroke and vascular dementia. The association with ischemic stroke was further investigated with its subtypes classified based on Trial of Org 10172 in Acute Stroke Treatment (TOAST). No significant association was observed for both G-395A and C1818T with ischemic stroke and vascular dementia (P>0.05). The analysis with subtypes of ischemic stroke revealed the associations that the A allele of G-395A increased the risk of cardioembolic stroke (CE, OR=2.60; P=0.006), and subjects carrying the A allele were susceptible to CE in both of dominant (AA+GA versus GG; OR=2.50; P=0.046) and recessive (AA versus GA+GG; OR=6.52; P=0.007) models. Further analysis of data partitioned by gender showed that the associations of G-395A with CE only existed in women (A versus G; OR=4.33; P=0.002), AA+GA versus GG; OR=5.68; P=0.014, and AA versus GA+GG; OR=9.07; P=0.012), but the significance disappeared in men (P>0.05). The sequence variant of G-395A in klotho might be a genetic risk factor for CE in females.
Neuroscience Letters 11/2006; 407(3):189-94. · 2.11 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Sequence variants of angiotensin converting enzyme (ACE) insertion/deletion (I/D), angiotensinogen (AGT) T235M, angiotensin II type 1 receptor (AT1R) A1166C, and plasminogen activator inhibitor-1 (PAI-1) 4G/5G were analyzed to see their genetic associations with vascular dementia as its candidate genetic risk factors involving renin-angiotensin and fibrin systems. While the ACE I/D, AT1R A1166C, and PAI-1 4G/5G did not contribute to the genetic susceptibility to vascular dementia (P>0.05), a significant association with vascular dementia was shown in the T235M polymorphism of AGT. The frequency of the M allele in patients was higher than in controls with the odds ratio (OR) estimate of 1.51 (P<0.05). In a dominant model, the TM+MM genotypes increased the risk of vascular dementia compared to the TT genotype (OR=2.01; P<0.001). The current results suggested that AGT T235M polymorphism might be a risk factor of vascular dementia.
Neuroscience Letters 07/2006; 401(3):276-9. · 2.11 Impact Factor
